Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

scAAV9 U7 ACCA

Drug Profile

scAAV9 U7 ACCA

Alternative Names: scAAV9.U7.ACCA

Latest Information Update: 08 Apr 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Audentes Therapeutics
  • Developer Astellas Gene Therapies; Nationwide Children's Hospital
  • Class Gene therapies; Small interfering RNA
  • Mechanism of Action Dystrophin expression stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Duchenne muscular dystrophy

Most Recent Events

  • 01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
  • 07 Feb 2020 Phase-I/II clinical trials in Duchenne muscular dystrophy (In infants, In children) in USA (Parenteral) (NCT04240314)
  • 07 Feb 2020 Preclinical data for Duchenne muscular dystrophy released by Audentes Therapeutics (NCT04240314)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top